Neural Noise

2026-03

5 min read

BCI Monthly Memo — March 2026

Bottom line: March saw major capital deployment and regulatory milestones on two continents—Science Corp’s $230M raise and China’s first commercial BCI approval—signaling that the race to bring neural interfaces to market is accelerating across both sensory restoration and motor rehabilitation domains.

Theme: The field is shifting from pure R&D toward commercial and clinical deployment, with geographic competition between U.S. and China intensifying while decoder and calibration bottlenecks increasingly define the frontier.

Industry Highlights

  • Science Corp closed a $230M Series C at a $1.5B post-money valuation, with the PRIMA retinal implant on track for European launch mid-2026 following CE mark application—potentially the first BCI company with a vision restoration product on the market.
  • Cognito Therapeutics raised ~$105M in Series C to advance its gamma-frequency Spectris headset through Alzheimer’s development, with new EEG data at AD/PD 2026 showing attenuation of EEG slowing.
  • Paradromics launched an academic collaboration programme to accelerate high-channel BCI development through external R&D partnerships.
  • Mave Health raised $2.1M for consumer neurotechnology wearables targeting focus and stress regulation.
  • MindMaze Therapeutics gained Baader Bank coverage with a Buy rating, boosting sell-side visibility for the Swiss-listed neuro-rehab company.
  • Jump Trading announced support for computational neuroscience talent at UCL, signaling industry investment in the neural decoding pipeline.

Research Signals

  • Cortical handwriting decoding: A Nature Communications paper demonstrated that motor cortex encodes handwriting as a multidimensional movement (3D velocity, grip force, pressure, EMG), with incorporating these features significantly improving BCI decoding performance.
  • Meta’s TRIBE foundation model: Meta AI introduced TRIBE, achieving 70x resolution gains in cross-individual, cross-language neural decoding via in-silico simulation—a major big-tech entry into neural decoding.
  • Bidirectional neuromorphic interface: A bioRxiv preprint presented a wireless system with on-device neuromorphic spike decoding for closed-loop optogenetics in freely moving animals—addressing a key miniaturization bottleneck.
  • Ultrasound wristband: Researchers developed a non-invasive wrist-worn device using AI to decode 22 degrees of freedom in real-time hand tracking from muscle/tendon kinematics.
  • Spike sorting evaluation: A Journal of Neurophysiology paper introduced effect-size metrics and power analysis for benchmarking spike sorters—foundational infrastructure for invasive BCIs.
  • Global HFO bursts: Human intracranial recordings revealed coordinated high-frequency oscillation bursts across cortex during memory encoding and retrieval, relevant to ECoG feature extraction.
  • Cross-participant encoding models: A rapid cortical mapping framework enables transfer learning to reduce per-subject calibration—directly applicable to BCI decoder training.
  • MI-BCI advances: New architectures including DSSICNN for graph-attention spectral networks, polarity-aware microstates, and MEAN multimodal fusion (EEG+ECG+EOG) pushed non-invasive decoding forward.

Clinical & Regulatory

  • China’s first commercial BCI: Borui Kang Medical Technology received regulatory clearance for a minimally invasive extradural system for restoring hand grasp in quadriplegia—widely reported as the first commercially authorized BCI medical device in its class.
  • PRIMA regulatory path: Science Corp submitted CE mark application for the PRIMA retinal implant, with European approval expected mid-2026 (Germany as first market) and ongoing FDA discussions.
  • Portable tACS for depression: A multicenter RCT in Nature Digital Medicine provides clinical trial evidence for at-home non-invasive brain stimulation, following Flow Neuroscience’s FDA approval for at-home tDCS.
  • DBS for treatment-resistant depression: Clinical trials targeting white matter tracts are expanding implanted neuromodulation beyond movement disorders.
  • Patient perception survey: A Frontiers study linked willingness to undergo ECoG implantation to hypothetical recovery level and rehabilitation priorities—informing consent and trial design.
  • DBS precision mapping: Nature Neuroscience studies provided dense longitudinal DBS circuit response mapping, actionable for closed-loop DBS personalization.

Market & Ecosystem

  • China competitive positioning: NeuCyber publicly stated it trails Neuralink by ~3 years, while the Beinao-1 semi-invasive system was showcased in Beijing—deliberate public positioning for national neural-interface efforts.
  • Science Corp unicorn status: The $1.5B valuation confirms strong investor confidence in the neural-implant sector pre-FDA decision.
  • Ceribell earnings: The clinical EEG company beat Q4 revenue estimates despite a loss, reflecting execution in bedside brain monitoring.
  • Neuralink manufacturing: Reports point to a push toward higher-volume production and automated surgical workflows in 2026.

Emerging Narratives

  • Decoder training as the real bottleneck: Commentary correctly highlights that calibration burden and data requirements—not implant hardware—remain the limiting factor for brain-to-text BCIs.
  • Global collaboration calls: A top scientist urged global collaboration on BCI development, pulling standards, safety, and shared R&D into diplomatic discourse.
  • Neural data governance: Policy discussions continue to stress the sensitive treatment of neural signals, with implications for privacy law and responsible BCI development.
  • Big tech enters neural decoding: Meta’s TRIBE model signals that large technology companies are investing seriously in foundation models for brain-signal interpretation.
  • Closed-loop neuromodulation momentum: Multiple studies this month advanced brain-state-dependent stimulation—EEG-gated rTMS, adaptive MI-BCI difficulty—pointing toward tighter integration of decoding and stimulation.

Further reading

Suggested titles

  • “Commercial BCIs Cross the Finish Line in China and Europe”
  • “The $335M Month: Capital Floods Into Neural Interfaces”
  • “Decoder Bottleneck, Not Implants, Defines the BCI Frontier”
  • “Science Corp, Borui Kang, and the Race to Market”
  • “From Lab to Living Room: At-Home Neuromodulation Arrives”

previous << monthly >> next

Graph View

Backlinks